Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Kamada stock

KMDA
IL0010941198
A0JMEX

Price

2.20
Today +/-
-0.03
Today %
-1.46 %

Kamada stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Kamada stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Kamada stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Kamada stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Kamada's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Kamada Stock Price History

DateKamada Price
2/14/20252.20 undefined
2/13/20252.23 undefined
2/12/20252.26 undefined
2/11/20252.23 undefined
2/10/20252.32 undefined
2/7/20252.16 undefined
2/6/20251.95 undefined
2/5/20251.99 undefined
2/4/20251.93 undefined
2/3/20251.89 undefined
1/31/20251.88 undefined
1/30/20251.87 undefined
1/29/20251.87 undefined
1/28/20251.90 undefined
1/27/20251.91 undefined
1/24/20252.00 undefined
1/23/20251.99 undefined
1/22/20252.12 undefined
1/21/20251.99 undefined

Kamada Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kamada, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kamada from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kamada’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kamada. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kamada’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kamada’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kamada’s growth potential.

Kamada Revenue, EBIT and net profit per share

DateKamada RevenueKamada EBITKamada Net Income
2026e197.21 M undefined24.09 M undefined21.31 M undefined
2025e178.53 M undefined22.01 M undefined20.33 M undefined
2024e164.42 M undefined19.04 M undefined14.27 M undefined
2023142.52 M undefined10.06 M undefined8.28 M undefined
2022129.3 M undefined4.5 M undefined-2.3 M undefined
2021103.6 M undefined-700,000 undefined-2.2 M undefined
2020133.2 M undefined19.2 M undefined17.1 M undefined
2019127.2 M undefined22.8 M undefined22.3 M undefined
2018114.5 M undefined19.3 M undefined22.3 M undefined
2017102.8 M undefined7.4 M undefined6.9 M undefined
201677.5 M undefined-5.5 M undefined-6.7 M undefined
201569.9 M undefined-11.4 M undefined-11.3 M undefined
201471.1 M undefined-11.5 M undefined-13.2 M undefined
201370.6 M undefined3.7 M undefined400,000 undefined
201272.7 M undefined4.2 M undefined300,000 undefined
201159.5 M undefined-2.5 M undefined-3.7 M undefined
201034.5 M undefined-10.2 M undefined-14.4 M undefined
200914.5 M undefined-15.8 M undefined-21.3 M undefined
200816.1 M undefined-18 M undefined-13.2 M undefined
200712.6 M undefined-15.3 M undefined-21.5 M undefined
200613.1 M undefined-4 M undefined-3 M undefined
200511.5 M undefined-2.8 M undefined1 M undefined
200410.3 M undefined-2.1 M undefined1.6 M undefined

Kamada Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
710111312161434597270716977102114127133103129142164178197
-42.8610.0018.18-7.6933.33-12.50142.8673.5322.03-2.781.43-2.8211.5932.4711.7611.404.72-22.5625.2410.0815.498.5410.67
14.2920.0018.1823.0825.00343.75392.8614.7127.1230.5637.1421.1321.7427.2731.3735.9638.5835.3429.1335.6638.7333.5430.9027.92
1223300516222615152132414947304655000
-211-3-21-13-21-14-300-13-11-66222217-2-28142021
--150.00--400.00600.00-38.1061.54-33.33-78.57----15.38-45.45-200.00266.67--22.73-111.76--500.0075.0042.865.00
9.49.49.49.410.513.220.226.727.628.733.43636.236.43840.440.644.644.844.853.68000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Kamada Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Kamada is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
20042005200620072008200920102011201220132014201520162017201820192020202120222023
                                       
0.45.28.63.913.330.946.441.233.874.251.928.328.64350.673.9109.318.634.355.64
2.84.3553.4412.97.113.917.917.523.119.830.727.923.322.335.327.719.92
0.40.32.22.10.91.41.720.62.31.21.921.321.90.80.30.71.37
3.46.36.45.78.18.110.715.320.521.925.426.325.621.129.343.24371.872.588.48
0000000.21.511.41.10.91.10.81.11.22.54.13.94.55
716.122.216.725.744.471.967.169.8117.797.180.577.196.9110.9143.5177.9130.1139.1169.96
5.35.38.212.714.317.719.917.418.821.421.821.322.225.22528.629.129.428.735.99
00000000000000000000
000000000100100000000000
000.20.10.20.1000.20.10.10.10.300.10.31.5153.6147139.96
00000000000000000000
001.43.220.50.30.60.2000002.11.42.15.67.69.01
5.35.39.81616.518.320.21819.221.62221.422.525.227.230.332.7188.6183.3184.95
12.321.43232.742.262.792.185.189139.3119.1101.999.6122.1138.1173.8210.6318.7322.4354.91
                                       
1.11.82.63.44.27.18.36.97.29.29.29.39.310.410.410.411.711.711.715.02
4.111.123.243.75783.9100.591.296.9157.1158.4162.2162.7177.9179.1180.8209.8210.2210.5265.85
-3.4-2.3-5.6-35.9-49.3-63.3-86.5-76.8-77-78.2-92.4-104.8-111.5-104.9-83-61.4-44.3-46.3-48.1-39.93
01.61.60.50.82.54.51.31.41.95.25.76.36.15.85.41.41.21.93.08
000000000001000001000000
1.812.221.811.712.730.226.822.628.59080.472.566.889.5112.3135.3178.6176.8176244.02
2.22.94.44.44.961212.512.214.116.516.916.31817.324.816.125.132.924.8
000000003.44.344.15.65.85.25.87.36.97.38.08
2.82.51.722.73810.48.25.531.94.94.90.50.60.218.23015.32
00000000000000000000
0.60.50.74.61.50.1005.48.77.500.40.60.61.51.33.85.51.38
5.65.96.8119.19.12022.929.232.63122.927.229.323.632.724.95475.749.59
42.82.93.118.920.923.322.418.77.500.21.41.40.74.23.620.615.17.44
00000000000000000000
10.40.46.91.42.722.217.212.89.37.76.44.41.91.51.53.467.255.553.86
53.23.31020.323.645.539.631.516.87.76.65.83.32.25.7787.870.661.29
10.69.110.12129.432.765.562.560.749.438.729.53332.625.838.431.9141.8146.3110.89
12.421.331.932.742.162.992.385.189.2139.4119.110299.8122.1138.1173.7210.5318.6322.3354.91
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Kamada provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Kamada's financial health and stability.

Assets

Kamada's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Kamada must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Kamada after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Kamada's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M USD)DEPRECIATION (M USD)DEFERRED TAXES (M USD)CHANGES IN WORKING CAPITAL (M USD)NON-CASH ITEM (M USD)PAID INTEREST (M USD)PAID TAXES (k USD)NET CASH FLOW FROM OPERATING ACTIVITIES (M USD)CAPITAL EXPENDITURES (M USD)CASH FLOW FROM INVESTING ACTIVITIES (M USD)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M USD)INTEREST INCOME AND EXPENSES (M USD)NET DEBT CHANGE (M USD)NET CHANGE IN EQUITY (M USD)CASH FLOW FROM FINANCING ACTIVITIES (M USD)CASH FLOW FROM OTHER FINANCING ACTIVITIES (USD)TOTAL DIVIDENDS PAID (M USD)NET CHANGE IN CASH FLOW (M USD)FREE CASH FLOW (M USD)SHARE-BASED COMPENSATION (M USD)
200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-210-3-21-13-21-14-300-13-11-66222217-2-28
00112222333233334451212
000000000000000000000
30-4-3110150-16-12-4-74-7-150-4-1310-19
0-1006-4873669311022284
000000222211000000001
00000000000001,0000000000
20-2-4-12-13-12100-8-3-9-1313102719-8284
-20-1-3-7-3-5-3-1-4-5-3-2-2-4-2-2-5-3-3-5
-20-1-3-6-3-5-22-1-2-3-26111-15-50-13-61-3-5
0000000-18021-23134-11-21-7-5700
000000000000000000000
00303123000-4-7-7100-1-118-9-35
00510101331702530101500240058
0081013263570249-7-61150-12318-922
---------1.00------------
000000000000000000000
0042-5916-4-1-742-44-94252427-511521
-0.42-0.88-3.72-8.07-19.26-17.39-17.746.39-0.99-12.87-9.49-13-16.7-0.74-0.567.6725.2713.62-12.5524.81-1.54
000000000000000000000

Kamada stock margins

The Kamada margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kamada. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kamada.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kamada's sales revenue. A higher gross margin percentage indicates that the Kamada retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kamada's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kamada's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kamada's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kamada. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kamada's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kamada Margin History

Kamada Gross marginKamada Profit marginKamada EBIT marginKamada Profit margin
2026e38.94 %12.21 %10.8 %
2025e38.94 %12.33 %11.39 %
2024e38.94 %11.58 %8.68 %
202338.94 %7.06 %5.81 %
202236.12 %3.48 %-1.78 %
202129.25 %-0.68 %-2.12 %
202035.74 %14.41 %12.84 %
201939.07 %17.92 %17.53 %
201836.24 %16.86 %19.48 %
201731.23 %7.2 %6.71 %
201627.61 %-7.1 %-8.65 %
201522.6 %-16.31 %-16.17 %
201421.1 %-16.17 %-18.57 %
201337.39 %5.24 %0.57 %
201231.22 %5.78 %0.41 %
201128.07 %-4.2 %-6.22 %
201016.81 %-29.57 %-41.74 %
2009-5.52 %-108.97 %-146.9 %
20080.62 %-111.8 %-81.99 %
200723.81 %-121.43 %-170.63 %
200623.66 %-30.53 %-22.9 %
200520.87 %-24.35 %8.7 %
200422.33 %-20.39 %15.53 %

Kamada Stock Sales Revenue, EBIT, Earnings per Share

The Kamada earnings per share therefore indicates how much revenue Kamada has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kamada earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kamada's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kamada’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kamada's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Kamada Revenue, EBIT and net profit per share

DateKamada Sales per ShareKamada EBIT per shareKamada Earnings per Share
2026e3.43 undefined0 undefined0.37 undefined
2025e3.11 undefined0 undefined0.35 undefined
2024e2.86 undefined0 undefined0.25 undefined
20232.66 undefined0.19 undefined0.15 undefined
20222.89 undefined0.1 undefined-0.05 undefined
20212.31 undefined-0.02 undefined-0.05 undefined
20202.99 undefined0.43 undefined0.38 undefined
20193.13 undefined0.56 undefined0.55 undefined
20182.83 undefined0.48 undefined0.55 undefined
20172.71 undefined0.19 undefined0.18 undefined
20162.13 undefined-0.15 undefined-0.18 undefined
20151.93 undefined-0.31 undefined-0.31 undefined
20141.97 undefined-0.32 undefined-0.37 undefined
20132.11 undefined0.11 undefined0.01 undefined
20122.53 undefined0.15 undefined0.01 undefined
20112.16 undefined-0.09 undefined-0.13 undefined
20101.29 undefined-0.38 undefined-0.54 undefined
20090.72 undefined-0.78 undefined-1.05 undefined
20081.22 undefined-1.36 undefined-1 undefined
20071.2 undefined-1.46 undefined-2.05 undefined
20061.39 undefined-0.43 undefined-0.32 undefined
20051.22 undefined-0.3 undefined0.11 undefined
20041.1 undefined-0.22 undefined0.17 undefined

Kamada business model

Kamada Ltd is an Israel-based company specializing in the development and marketing of biopharmaceutical products for humans and animals. The company was founded in 1990 by a team of experienced executives and scientists from the biotech industry. Since its inception, Kamada has become a global leader in plasma fractionation and the production of antibodies and enzymes. The company is listed on the NASDAQ and the Tel Aviv Stock Exchange and has over 450 employees in its facilities in Israel and the USA. Kamada's business model is based on combining innovative science and technology to develop products and therapies for rare and severe diseases. The company is constantly working to improve its production processes to deliver more efficient and cost-effective products. Kamada operates in three divisions: human therapeutics, veterinary medicine, and plasma research. The human therapeutics division develops and markets products for the treatment of diseases such as alpha-1 antitrypsin deficiency, immunoglobulin deficiency, hemophilia, and other serious conditions. The veterinary medicine division offers products for the treatment of diseases in dogs, horses, and cows to veterinary professionals. The plasma research division focuses on developing technologies for the production of plasma derivatives and discovering new applications for plasma proteins. Kamada has a wide range of products on the market, including its flagship product Glassia, which is used to treat alpha-1 antitrypsin deficiency, a rare genetic disease that can affect the lungs. The company also produces intravenous immunoglobulin preparations for the treatment of immune deficiencies and other immune system disorders, as well as recombinant factor VIII for the treatment of hemophilia. In veterinary medicine, Kamada offers products such as Equine Seramune, designed for horses and used to treat life-threatening infections caused by bacteria found in the intestines of horses. The company also produces products for the treatment of mastitis, an infection of the milk ducts in cows, and gastrointestinal tract infections in dogs. Kamada takes pride in playing a leading role in plasma research and technology. The company's research has resulted in groundbreaking technologies that allow for the faster and more cost-effective production of important plasma proteins than was previously possible. Kamada works closely with other research institutions and companies to collaborate on solutions for severe and rare diseases. Over the years, Kamada has received numerous awards and recognition for its groundbreaking research and development work. The company is committed to continuing to develop innovative products and therapies to improve the lives of patients with rare and severe diseases. Overall, Kamada Ltd has experienced remarkable growth in recent years. It is a company that plays a leading role in the market for biopharmaceutical products based on top-notch scientific research and efficient technology. In the future, Kamada will undoubtedly continue to develop groundbreaking products and therapies to improve the lives of patients worldwide. Kamada is one of the most popular companies on Eulerpool.com.

Kamada SWOT Analysis

Strengths

Kamada Ltd has several key strengths that contribute to its success in the market. These strengths include:

  • Strong brand recognition and reputation
  • Robust product portfolio with a focus on high-quality medical solutions
  • Established distribution channels and strategic partnerships
  • Advanced research and development capabilities
  • Global presence and market reach

Weaknesses

Despite its strengths, Kamada Ltd also has some weaknesses that it needs to address in order to maintain its competitive position:

  • Reliance on a limited number of key suppliers
  • Higher production costs compared to some competitors
  • Dependence on regulatory approvals and compliance
  • Limited diversification in product offerings
  • Product recall risks

Opportunities

There are various opportunities available for Kamada Ltd to further expand its business and drive growth:

  • Increasing demand for innovative medical solutions globally
  • Emerging markets with untapped potential
  • Advancements in technology driving new product development
  • Collaboration opportunities with research institutions and healthcare providers
  • Expansion into new therapeutic areas

Threats

Kamada Ltd faces certain threats that could potentially impact its performance and market position:

  • Intense competition from established and emerging players
  • Regulatory challenges and changing healthcare policies
  • Volatility in raw material prices
  • Economic uncertainties affecting healthcare spending
  • Intellectual property infringement risks

Kamada Revenue by Segment

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Kamada Revenue by Segment

Segmente2021
Proprietary Products75.52 M USD
Distribution28.12 M USD

Kamada Revenue by Region

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Kamada Revenue by Segment

DateAsiaEuropeIsraelLatin AmericaOthersU.S.A and North America
20213.17 M USD5.68 M USD35.77 M USD9.13 M USD134,000 USD49.76 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Kamada Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Kamada historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Kamada shares outstanding

The number of shares was Kamada in 2024 — This indicates how many shares 53.676 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Kamada earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Kamada's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Kamada’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Kamada's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Kamada.

Kamada latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20240.07 USD0.07 USD (2.94 %)2024 Q3
6/30/20240.06 USD0.08 USD (38.41 %)2024 Q2
3/31/20240.06 USD0.04 USD (-34.64 %)2024 Q1
12/31/20230.05 USD0.09 USD (76.47 %)2023 Q4
9/30/20230.03 USD0.06 USD (96.08 %)2023 Q3
6/30/20230.02 USD0.04 USD (96.08 %)2023 Q2
3/31/20230.03 USD-0.04 USD (-256.86 %)2023 Q1
12/31/20220.07 USD0.07 USD (5.58 %)2022 Q4
9/30/2022-0.03 USD0.01 USD (132.68 %)2022 Q3
6/30/2022-0.02 USD-0.09 USD (-341.18 %)2022 Q2
1
2
3
4
...
5

Kamada shareholders

%
Name
Stocks
Change
Date
38.41414 % First Israel Mezzanine Investors Ltd.22,084,287012/31/2023
4.97085 % Gov Financial Holdings, Ltd.2,857,741-37,90312/31/2023
3.18830 % Phoenix Investment and Finances Ltd1,832,952-84,5256/30/2024
2.47529 % The Vanguard Group, Inc.1,423,04698,0206/30/2024
1.45470 % Renaissance Technologies LLC836,305-11,1006/30/2024
1.26311 % More Investment House Ltd.726,161690,8426/30/2024
1.10934 % Wells Fargo Advisors637,76012,9936/30/2024
1.09783 % Recanati (Leon Yehuda)631,145-46,33412/31/2023
1.05745 % Tsur (David)607,929012/31/2023
0.64582 % Dimensional Fund Advisors, L.P.371,28108/31/2024
1
2
3
4
5
...
7

Kamada Executives and Management Board

Mr. David Tsur

(73)
Kamada Deputy Chairman of the Board (since 2015)
Compensation 2.86 M USD

Dr. Ruth Wolfson

(69)
Kamada Senior Vice President - Scientific Affairs
Compensation 619,000 USD

Ms. Lilach Asher Topilsky

Kamada Chairman of the Board (since 2020)

Mr. Amir London

(47)
Kamada Chief Executive Officer

Mr. Chaime Orlev

(51)
Kamada Chief Financial Officer
1
2
3
4
5
...
6

Most common questions regarding Kamada

What values and corporate philosophy does Kamada represent?

Kamada Ltd represents values of innovation, dedication, and excellence. Committed to improving patients' lives, Kamada focuses on developing and commercializing plasma-derived protein therapeutics. With a corporate philosophy centered on integrity, transparency, and ethical conduct, the company aims to deliver high-quality treatments and meet the medical needs of diverse patient populations. By prioritizing research and development initiatives, Kamada strives to leverage its scientific expertise and technological advancements to address unmet medical needs. Through collaboration and partnership, Kamada Ltd is dedicated to making a positive impact in the healthcare industry, promoting patient well-being, and advancing medical advancements.

In which countries and regions is Kamada primarily present?

Kamada Ltd is primarily present in multiple countries and regions worldwide. With a strong global presence, the company operates in various key markets, including the United States, Canada, Europe, Israel, and Latin America. Kamada Ltd's diversified geographical footprint enables it to reach a wide range of customers and expand its distribution network effectively.

What significant milestones has the company Kamada achieved?

Kamada Ltd has achieved several significant milestones throughout its operation. The company demonstrated its dedication to innovation and development by receiving approval for several therapeutic products. For instance, in 2011, Kamada obtained FDA approval for Glassia, its flagship treatment for Alpha-1 Antitrypsin Deficiency. Additionally, the company successfully launched AATscan, a diagnostic tool used for detecting the presence of Alpha-1 Antitrypsin Deficiency. Furthermore, Kamada established partnerships with renowned global pharmaceutical companies, expanding its market presence and enhancing its research and development capabilities. These accomplishments highlight Kamada Ltd's commitment to advancing medical solutions and solidify their position as a leading player in the healthcare industry.

What is the history and background of the company Kamada?

Kamada Ltd is a pharmaceutical company based in Israel. Founded in 1990, the company specializes in the development and production of plasma-derived protein therapeutics. With a focus on rare diseases and respiratory conditions, Kamada's innovative therapies have gained recognition globally. The company has a strong track record of successful partnerships with leading pharmaceutical companies and has expanded its market reach across Europe, the United States, and other regions. Kamada's dedication to research and development has resulted in numerous approvals from regulatory authorities, enhancing its reputation as a leader in the biopharmaceutical industry. Through its commitment to providing life-saving treatments, Kamada Ltd continues to improve the well-being of patients worldwide.

Who are the main competitors of Kamada in the market?

The main competitors of Kamada Ltd in the market are companies like Takeda Pharmaceutical Company Limited, CSL Limited, and Grifols, S.A. These companies also operate in the biopharmaceutical industry and offer similar products and services. However, Kamada Ltd distinguishes itself through its innovative research and development efforts, strong global presence, and a diverse product portfolio. Its commitment to technological advancements and strategic partnerships enables Kamada Ltd to stay competitive and maintain a significant market position.

In which industries is Kamada primarily active?

Kamada Ltd is primarily active in the biopharmaceutical industry.

What is the business model of Kamada?

The business model of Kamada Ltd revolves around the development, production, and commercialization of specialty plasma-derived protein therapeutics. Kamada focuses on three main areas: respiratory diseases, AAT Deficiency, and graft-versus-host disease. By utilizing advanced technologies and expertise in protein purification, Kamada aims to provide innovative solutions for patients and healthcare professionals. With its comprehensive portfolio of FDA-approved products and strategic partnerships, Kamada strives to improve the quality of life for individuals facing these medical conditions. As a leading biopharmaceutical company, Kamada Ltd leverages its extensive knowledge and resources to bring transformative therapies to the market.

What is the P/E ratio of Kamada 2025?

The Kamada P/E ratio is 5.8.

What is the P/S ratio of Kamada 2025?

The Kamada P/S ratio is 0.66.

What is the Quality Investing of Kamada?

The Quality Investing for Kamada is 4/10.

What is the revenue of Kamada 2025?

The expected Kamada revenue is 178.53 M USD.

How high is the profit of Kamada 2025?

The expected Kamada profit is 20.33 M USD.

What is the business model of Kamada

Kamada Ltd. is a biopharmaceutical company based in Israel that specializes in the development, manufacturing, and marketing of products for the treatment of various diseases. The company's business model is based on its ability to produce innovative products based on proteins that are relevant for the therapy of diseases such as Alpha-1 antit... The company's main areas of focus include the production of intravenous immunoglobulins (IVIG) for the treatment of severe immunodeficiency disorders. IVIG is also used in the treatment of autoimmune diseases such as rheumatoid arthritis and lupus. Kamada is currently the only manufacturer of IVIG in Israel. The company's products are also available in Europe and the USA. Another important area of the company is the production of alpha-1 proteinase inhibitors (AAT) for the treatment of alpha-1 antitrypsin deficiency. This is an inherited disease that can lead to severe lung damage. Kamada has introduced the first AAT product manufactured in Israel to the market. It is also distributed in Europe and the USA. In addition to IVIG and AAT, Kamada also produces Factor VIII concentrates for the treatment of hemophilia and for blood clotting in patients who have received blood transfusions. The company also manufactures enzymes for the diagnosis of diseases and for research. Another business area of the company is the development of biosimilars, which mimic biological medicines that are already on the market. Kamada's biosimilars will help improve access to important therapies and relieve healthcare systems. Currently, the company is developing biosimilars for use in lung diseases and malignant diseases. Kamada's business model also includes collaboration with other companies in the biotechnology industry. The company has partnerships with leading companies such as Baxter, Shire, and Novartis to distribute or co-develop its products. In summary, Kamada's business model is focused on producing and marketing innovative products for the treatment of various diseases. The company specializes in protein production and has partnerships with other biotechnology companies. The different divisions of the company include the production of IVIG, AAT, Factor VIII concentrates, enzymes, and biosimilars. Kamada is also involved in the development of new products to meet patient needs and improve access to important therapies.

What is the Kamada dividend?

Kamada pays a dividend of 0 USD distributed over payouts per year.

How often does Kamada pay dividends?

The dividend cannot currently be calculated for Kamada or the company does not pay out a dividend.

What is the Kamada ISIN?

The ISIN of Kamada is IL0010941198.

What is the Kamada WKN?

The WKN of Kamada is A0JMEX.

What is the Kamada ticker?

The ticker of Kamada is KMDA.

How much dividend does Kamada pay?

Over the past 12 months, Kamada paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Kamada is expected to pay a dividend of 0 USD.

What is the dividend yield of Kamada?

The current dividend yield of Kamada is .

When does Kamada pay dividends?

Kamada pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Kamada?

Kamada paid dividends every year for the past 0 years.

What is the dividend of Kamada?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kamada located?

Kamada is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kamada kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kamada from 2/18/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 2/18/2025.

When did Kamada pay the last dividend?

The last dividend was paid out on 2/18/2025.

What was the dividend of Kamada in the year 2024?

In the year 2024, Kamada distributed 0 USD as dividends.

In which currency does Kamada pay out the dividend?

The dividends of Kamada are distributed in USD.

All fundamentals about Kamada

Our stock analysis for Kamada Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kamada Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.